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Leucocyte chemotactic factor 2 (ALECT2) amyloidosis 
Leucocyte chemotactic factor 2 (ALECT2) amyloidosis is a newly identified form of 
renal amyloidosis which, according to US biopsy series, is the third most common form 
of renal amyloid. Here we detail for the first time the epidemiology and ethnic 
preponderance to this disease in a European country, which differs substantially from 
that in North America, and determine both renal and patient outcomes in a cohort 





Introduction: Renal biopsy series from North America suggest that leucocyte 
chemotactic factor 2 (ALECT2) amyloid is the third most common type of renal 
amyloid.  We report the first case series from a European Centre of prevalence, clinical 
presentation, and diagnostic findings in ALECT2 amyloidosis and report long term 
patient and renal outcomes for the first time. 
 
Methods: We studied the clinical features, diagnostic investigations and outcome of 
all patients with ALECT2 amyloidosis followed systematically at the UK National 
Amyloidosis Centre (NAC) between 1994 and 2015. 
 
Results: Twenty-four patients, all non-Caucasian, were diagnosed with ALECT2 
amyloidosis representing 1.3% of all patients referred to the NAC with biopsy proven 
renal amyloid.  Diagnosis was made at median age 62 years, usually from renal 
histology; immunohistochemical staining was definitive for ALECT2 fibril type.  
Median eGFR at diagnosis was 33 ml/min and median proteinuria was 0.5 g/24 hr.  
Hepatic amyloid was evident on SAP scintigraphy in 11/24 cases but was not associated 
with significant derangement of liver function.  No patient had evidence of cardiac 
amyloidosis or amyloid neuropathy.  Median follow up was 4.8 (0.5-15.2) years during 
which 4 patients died and 4 progressed to ESRD.  Mean rate of GFR loss was 4.2 (0.5-
9.6) ml/min/year and median estimated renal survival from diagnosis was 8.2 years.  
Serial SAP scans revealed little or no change in total body amyloid burden.   
 
Conclusions: ALECT2 amyloidosis is a relatively benign type of renal amyloid, 
associated with a slow GFR decline, which is reliably diagnosed on renal histology.  
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Neither the molecular basis nor the factors underlying the apparent restriction of 
ALECT2 amyloidosis to non-Caucasian populations have been determined.   
 
Key Words: Amyloidosis, End Stage Renal Disease (ESRD), proteinuria, Chronic 
Kidney Disease (CKD), Leucocyte Chemotactic Factor 2 Amyloidosis (ALECT2)
Introduction 
Renal amyloidosis results from the pathological deposition of amyloid protein fibrils in 
glomeruli and/or renal parenchyma.  The diagnosis of amyloid is based on light 
microscopy demonstrating characteristic green birefringence in affected tissues that 
have been stained with Congo red and viewed under crossed polarized light.  More than 
30 different human proteins can form amyloid in vivo, which on electron microscopy 
appears as randomly orientated non-branching fibrils of 7-12 nm width.  The 
commonest form of amyloid diagnosed in kidney biopsies is AL type, in which the 
fibrils are derived from monoclonal immunoglobulin light chain.  Some 13 other 
proteins that can deposit as amyloid in the kidneys include serum amyloid A protein 
(SAA), apolipoproteins A-I, A-II and C-III, fibrinogen, lysozyme, gelsolin and 
transthyretin.1 
 Leucocyte chemotactic factor 2 (ALECT2) amyloidosis was first described in 
2008 in a 61-year-old woman who had presented seven years earlier with nephrotic 
syndrome and glomerular amyloid deposits and later underwent nephrectomy for clear 
cell renal carcinoma.2  Murphy et al subsequently described a series of ten adults with 
ALECT2 amyloid who presented with varying degrees of renal impairment, proteinuria 
and extensive interstitial and mesangial amyloid deposits.  Interestingly, all affected 
individuals were homozygous for the G allele, a polymorphism which results in a 
substitution of isoleucine with valine at position 40 in the mature LECT2 protein.3  Two 
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recent retrospective studies, one from the Mayo Clinic and the other from Nephropath 
which included 72 and 40 patients respectively have established the clinical and 
pathological characteristics and outcomes in renal ALECT2 amyloidosis in the U.S.4-6  
A retrospective U.S. renal biopsy series of 285 samples identified ALECT2 amyloid as 
the third most common type of renal amyloid at 2.5%.7  In a retrospective study of 130 
cases of hepatic amyloid, the Mayo Clinic investigators identified ALECT2 amyloid in 
25% of cases making it the second commonest form of hepatic amyloid.8  They 
identified unique pathological and clinical features, including the fact that the diagnosis 
of amyloid was often incidental, starkly contrasting with hepatic AL amyloid in which 
hepatomegaly and liver dysfunction are typical.   
There have been few studies worldwide and none from Europe exploring long 
term follow up and outcome in ALECT2 amyloidosis.  Here we report the prevalence, 
clinical presentation, diagnostic findings and long term outcome among all 24 patients 
who were diagnosed with ALECT2 amyloidosis at the UK National Amyloidosis 
Centre over a 21 year period. 
 
Methods 
Patients and Outcomes 
We included in this study all patients with ALECT2 amyloidosis who attended the UK 
National Amyloidosis Centre over a period of greater than 20 years (1994 to 2015).  
Nine of 24 patients were identified to have ALECT2 amyloidosis retrospectively and 
the remainder were diagnosed with ALECT amyloidosis at the time of diagnosis of 
amyloid.  Patients attended the NAC for their initial diagnostic evaluation and were 
followed up at regular (usually 12 monthly) intervals.  Investigations undertaken at each 
visit to the centre included detailed blood and urine biochemistry, electrocardiography, 
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echocardiography and monitoring of visceral organ involvement as well as whole body 
amyloid load by 123I-SAP scintigraphy.  Additional investigations were undertaken 
when clinically indicated.   
All patients were managed in accordance with the declaration of Helsinki and 
informed patient consent and institutional review board approval from the Royal Free 
Hospital Ethics committee were obtained for this study. 
 
Histology and Immunohistochemistry 
Renal (n=20), hepatic (n=4) and rectal (n=1) biopsies were processed, as previously 
described (one patient had both liver and renal biopsies).9  Briefly, serial sections were 
cut from each formalin fixed paraffin embedded block (FFPE).  Amyloid was 
diagnosed on Congo red staining by apple green birefringence when viewed under cross 
polarized light microscopy.  Paraffin embedded sections of 2 µm thickness were used 
for IHC, and sections of 6 µm thickness were used for Congo red and IHC/Congo red 
overlay, as previously decribed.9  Immunohistochemical staining of the amyloid 
deposits was performed using an extensive panel of monospecific antibodies reactive 
with serum amyloid A protein (SAA) (Euro Diagnostica AB), kappa and lambda 
immunoglobulin light chains (Dako), apolipoprotein A-I (Genzyme), fibrinogen Aα-
chain (Calbiochem®), transthyretin (Dako), and LECT2 (R & D Systems).  The goat 
anti-human LECT2 antibody (cat no AF722), was used at 1:600 dilution.  Staining 
specificity was determined by prior absorption of the antiserum with purified human 
protein, in these cases with human LECT2, which resulted in complete abrogation of 
staining.  IHC was performed on the Sequenza™ (Fisher Scientific, UK) platform using 
Impress™ (Vector laboratories UK) detection kit following the standard method, with 
the use of  a metal enhanced DAB Substrate kit (Thermo Scientific, UK) for visualizing 
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the immuno compound. All slides were viewed on a DM4000 (Leica Microsystems, 
UK) and was interpreted independently by two experienced operators.   
 
Proteomic analysis of amyloidotic tissue 
Laser micro dissection (LMD) followed by liquid chromatography and tandem mass 
spectrometry (MS) (LC-MS/MS) was performed on Congo red-positive glomeruli or 
renal tubules as previously described by Dogan and colleagues.10  For comparison, 
purified human LECT2 protein was trypsinized and analyzed by LC-MS/MS on a Velos 
orbitrap mass spectrometer.  MS data files were analyzed using Mascot11 to search the 
SwissProt database (SIB Bioinformatics Resource, Bethesda, MD).  Searches were 
conducted based on trypsin as the digestion enzyme and oxidation of methionine set as 
a variable modification; mass tolerances were 10 ppm for precursor ions and 0.60 Da 
for fragment ions. 
 
Genetic Analysis 
Genomic DNA was extracted from whole blood treated with EDTA as previously 
described.12  Coding regions of the LECT2 gene (NCBI Ref NC_000005.10) were 
amplified by polymerase-chain-reaction assay (PCR) and analyzed by automated 
sequencing as previously described.2  PCR products were purified with a QIAquick 
PCR purification kit (Qiagen) according to the manufacturer’s protocol and sequenced 
with the Big Dye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). The 
electropherograms of the LECT2 gene were analysed on the ABI 3130xl Genetic 
Analyser using Sequencing Analysis Software version 5.4. 
 
123I-Labelled SAP Scintigraphy 
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All patients underwent whole body anterior and posterior scintigraphic imaging 24 h 
after administration of 123I-labelled serum amyloid P component (SAP) using a GE 
Infinia Hawkeye gamma camera (GE Healthcare, Iowa, MN), as previously 
described.13  Labelled SAP studies were interpreted by a panel of physicians with 
experience of over 29 000 SAP scans. 
 
Statistical Methods  
Patient survival, time from diagnosis of amyloidosis to end-stage renal disease defined 
as commencement of renal replacement therapy (renal survival) and survival from 
commencement of renal replacement therapy were estimated by Kaplan-Meier 
analyses.  Censor date was 1st December 2015.  Rate of decline of renal function was 
analyzed in those patients who were not requiring renal replacement therapy at the time 




Twenty-four patients were confirmed to have ALECT2 amyloidosis at the UK National 
Amyloidosis Centre (NAC), comprising 0.36% of 6739 patients with amyloidosis and 
1.3% of 1853 patients with biopsy proven renal amyloid seen at the centre between 
1994 and 2015. Of these 24 cases, 9 were diagnosed retrospectively after the discovery 
of ALECT2 amyloidosis in 2008 having previously been classified as amyloid with no 
immunospecific staining.  Twenty-two patients had a renal presentation with 
proteinuria and/or impaired renal excretory function, including 20 who had been 
referred to the NAC on the basis of amyloid detected in a kidney biopsy.  Four patients 
had amyloid detected on liver histology (including one with established amyloid 
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deposits in the kidneys), performed in 3 of the 4 cases to investigate chronic viral 
hepatitis infection and in the last case as work up for peritoneal pseudomyxoma. The 
diagnosis of ALECT2 amyloidosis was therefore established on renal histology in 20 
cases, liver histology in 3 cases and on rectal histology in the remaining case (Table 1). 
Median age at diagnosis was 62 years (range 37–75), and male to female ratio 
was roughly equal (14/10).  Notably, 16 (67%) patients were from the Indian 
subcontinent (India and Pakistan), 7 (30%) patients were of Middle Eastern ancestry 
(Egyptian and Sudanese), and one was of Mexican origin.  ALECT2 amyloidosis was 
not diagnosed in any British Caucasians.  Patient demographics at diagnosis are shown 
in Table 1.   
 Two patients had established ESRD and were receiving renal replacement 
therapy in the form of hemodialysis at the time of diagnosis of ALECT2 amyloidosis.  
Neither had presented with nephrotic syndrome.  Among the remaining 22 patients who 
remained dialysis independent at the time of diagnosis, median eGFR was 33 ml/min 
(range 15-110) and median proteinuria was 0.5 g/24 hr (range 0.1-2.9).   
 Liver function tests were entirely normal among 21 patients.  There was mild 
elevation of transaminases (ALT 54 and 73 U/L) in 2 patients and mildly obstructive 
liver function in a single patient as evidenced by an alkaline phosphatase of 150 U/L.  
No patient had hyperbilirubinaemia or clinical evidence of jaundice.   
No patient had clinical, echocardiographic or cardiac biomarker evidence of 
cardiac amyloidosis or clinical evidence of amyloid peripheral or autonomic 
neuropathy. 
None of the 24 patients had evidence of a monoclonal gammopathy.  Four 





Renal histology revealed amyloid throughout the kidneys, often with bright congophilia 
and ‘sparkly glistening’ apple green birefringence when viewed under crossed 
polarized light.  Liver histology revealed amyloid deposits with a similar ‘sparkly 
glistening’ appearance under crossed polarized light.   
Among 20 patients who underwent renal biopsies, the vast majority (85%) had 
amyloid in the renal cortical interstitium which was sometimes extensive and often 
associated with tubular atrophy.  Amyloid deposits were identified in the tubular 
basement membranes in approximately one third of renal biopsies and in the vessel 
walls in two thirds (Table 2).  Glomerular amyloid was present in more than 70% of 
renal biopsies, and was associated with mesangial matrix expansion which was usually 
diffuse and global (Figure 1A and 1B).  Typically, a proportion of biopsied glomeruli 
were globally sclerosed.  The burden of amyloid within each compartment of the kidney 
varied substantially between patients, and apart from the extensive interstitial amyloid 
observed in some patients, there was no ‘characteristic’ pattern of deposition or 
apparent relationship between ethnicity and localization of renal amyloid deposits.   
Liver histology revealed amyloid deposits in vessel walls and globular deposits 
in the portal tracts (Figure 1D and 1E).  Gastrointestinal histology showed amyloid in 
the submucosa.  The amyloid stained specifically with anti-LECT2 antibody in every 
case (Figure 1C and 1F). 
 
Proteomic Analyses 
Proteomic analysis of the excised amyloid was performed in 14/24 samples.  LECT2 
was identified in 12/14 cases; there was insufficient material for valid interpretation of 
proteomic results in the two negative cases, each of which had <30 proteins identified 
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in the sample (both of whom were diagnosed on the basis of immunohistochemistry).  
A positive control sample of authentic LECT2 treated in the same way as the patient 
samples identified LECT2 with 95% protein coverage.   
 
Genetic Analyses 
All patients underwent genetic analysis and all except one affected individual were 
found to be homozygous for the G allele, a polymorphism which results in a substitution 
of isoleucine with valine at position 40 in the mature protein.  The remaining affected 
individual was heterozygous for the G allele, which as far as the authors are aware, is 
the first report of ALECT2 amyloidosis in a patient who is heterozygous for this allele.   
 
123I-Labelled SAP Scintigraphy 
SAP scintigraphy at diagnosis showed extra-renal amyloid deposits in most patients; 
21/24 (88%) had splenic amyloid, 11/24 (46%) had hepatic amyloid and 9/24 (38%) 
had adrenal gland involvement by amyloid despite preserved adrenocortical function in 
every case.  The adrenal glands were masked by heavy overlying liver and spleen 
amyloid deposits in 8 of the 15 remaining cases.   
Serial SAP scintigraphy, with an interval between the diagnostic and latest scan 
of up to 10 years, revealed little change in total body amyloid burden.  There was no 
evidence of amyloid regression from any organ in any patient but, interestingly and 
uncharacteristically for untreated systemic amyloidosis, nor was there evidence of 
accumulation of amyloid within the liver, kidneys or spleen over prolonged periods 
(Figure 2).   
 
Renal and Patient Outcomes 
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Median follow up in the whole cohort was 4.8 years (range 0.5–15.2).  During this time, 
4 patients died.  The cause of death was known in 3 cases who died from 
bronchopneumonia, cardiac arrest secondary to underlying ischaemic heart disease 
(IHD), and ‘pump failure’ secondary to aortic stenosis respectively.  Median age at 
death was 74 years (range 63–77).  Median estimated patient survival from diagnosis 
of ALECT2 amyloidosis was 15.1 years (Figure 3a).   
 Among 22 patients who were dialysis independent at diagnosis, mean rate of 
GFR loss was 4.2 ml/min/yr (range 0.5-9.6).  Four patients progressed to ESRD during 
follow up.  Median estimated time from diagnosis to ESRD by Kaplan Meier analysis 
among those 22 patients was 8.2 years (Figure 3b).  Proteinuria remained sub-nephrotic 
and serum albumin remained within the normal range in all patients throughout follow 
up.  Indeed there was no significant change in proteinuria over time among most 
patients (mean change <0.1 g/24hr/yr). 
 
Discussion 
LECT2 was reported to be a new amyloid fibril protein by Benson and colleagues in 
2008 following discovery of unanticipated amyloid within a nephrectomy specimen 
from an individual with co-existing clear cell renal carcinoma.2  LECT2 is a 16 kDa 
protein consisting of 151 amino acids, including an 18 amino acid signal peptide.  The 
amyloidogenic fibril protein in ALECT2 amyloidosis is composed of the entire 133-
residue peptide.  Although there is no mutation in the LECT2 gene associated with 
ALECT2 amyloidosis, nearly all affected individuals in our series, including two 
affected first degree relatives, were found to be homozygous for the G allele, a 
polymorphism which results in a substitution of isoleucine with valine at position 40 in 
the mature protein, consistent with previous reports.2  The G/G genotype has an overall 
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frequency of 0.477 and in subjects of European descent it is found at a frequency range 
of 0.6-0.7,2 although the frequency of this polymorphism in the studied population is 
unknown.  Murphy et al described a clear ethnic distribution in their case series of ten 
patients with ALECT2 amyloidosis; 7 of the 10 patients were of Mexican American 
origin,3 a finding corroborated by the Nephropath investigators who found that the 
majority of patients with ALECT2 amyloidosis were of Hispanic origin.14  A recent 
biopsy series revealed ALECT2 amyloid to be the second commonest type of renal 
amyloid in Egypt, accounting for almost one third of cases.15  Our cohort of 24 patients 
further supports an ethnic bias but includes individuals from the Indian Subcontinent 
and Egypt/Sudan as well as Hispanics, corroborating the recent findings of Larson et 
al.14 
The aetio-pathogenetic mechanisms underlying ALECT2 amyloid formation 
require further evaluation.  LECT2 is mostly produced by the liver and is known to be 
a chemotactic factor to neutrophils while it also stimulates the growth of chondrocytes 
and osteoblasts.16  Lin Bin et al identified LECT2 as an acute phase reactant with a high 
level of induction upon infection,17 and it appears to play a role in liver regeneration.18  
One might speculate therefore, that LECT2 is an acute phase reactant that is specifically 
triggered by a chronic hepatic infection or chronic hepatic inflammation and that the 
combination of the G/G genotype and excessive production of LECT2 by the liver 
predispose to development of amyloid.  Other proposed mechanisms for ALECT2 
amyloidosis included interference in the catabolic or transport pathways of LECT2 
resulting in an increased local tissue concentration or alterations in a binding partner of 
the LECT2 protein in the serum resulting in increased free circulating LECT2 levels.6  
Due to the absence of a commercially available LECT2 assay, we were unable to 
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measure plasma LECT2 concentration among our patient cohort in order to further 
explore these possibilities.   
The vast majority of patients diagnosed with ALECT2 amyloidosis had a renal 
presentation characterized by low level proteinuria and a reduced GFR.  Given the 
frequent (>70%) glomerular involvement by amyloid in this cohort, the absence of 
heavy proteinuria is surprising, and contrasts other types of renal amyloid in which the 
glomeruli are involved which are typically characterized by the nephrotic syndrome.  
Around half of patients with ALECT2 amyloidosis had evidence of liver involvement 
by SAP scintigraphy but liver synthetic function was preserved in every case and liver 
function abnormalities were absent or mild, consistent with previous reports.4  Three 
patients were diagnosed on liver histology, prompted in each case by another potential 
cause of liver dysfunction; presence of amyloid may have been incidental to the 
dysfunction since amyloid deposits were frequently present among those without 
derangement of liver function.  No patient had cardiac amyloidosis at diagnosis and 
clinically significant pulmonary or neural amyloid was not observed.   
Staining of formalin fixed paraffin embedded renal and liver sections with an 
anti-LECT2 antibody was unequivocally diagnostic in every case.  There was no 
background or non-specific staining of the sections, and the amyloid deposits were 
avidly and specifically stained by the antibody in both tissues.  The 
immunohistochemistry was corroborated by proteomic analysis of amyloid whenever 
this was undertaken on adequate samples.  The authors would therefore recommend 
that tissue from all cases of suspected ALECT2 amyloidosis is stained 
immunohistochemically and/or analyzed by tandem mass spectrometry. 
Despite absence of amyloid-specific therapy for ALECT2 amyloidosis, its 
natural history, described here in detail for the first time, is slow.  Mean rate of GFR 
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loss was 4.2 mls/min/year contrasting the typical decline in other types of renal 
amyloidosis (Table 3), such as untreated renal AL amyloidosis in which median time 
from diagnosis to ESRD is only about 12 months;19 only 6 patients in the whole cohort 
reached ESRD despite prolonged follow up.  Serial SAP scans, performed up to a 
decade apart, revealed absence of amyloid accumulation and similarly, no patient 
developed cardiac or neuropathic amyloid during follow up.  Consequently, median 
estimated patient survival from diagnosis was more than 15 years.   
Given the discrepancy between the clinical and histological prevalence of 
ALECT2 amyloid and the often insidious nature of its clinical manifestations, 7 the true 
prevalence of this type of amyloid may be greater than is currently recognized.  Since 
promising novel therapies to remove existing amyloid deposits are now under 
development,20 the diagnosis of ALECT2 amyloidosis ought to be considered in any 
non-Caucasian patient with renal amyloid deposits who has low level proteinuria, even 
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Table 1.  Patient demographics 
No Age at 
diagnosis/ 
Sex 












1 61 M Egyptian Renal and hepatic C 201 30 0.17 L/S/K 
2 62 M Egyptian Renal -ve 245 24 0.10 L/S 
3 58 F Egyptian Renal -ve 116 44 0.47 L/S/K/A 
4 62 M Egyptian Renal -ve 219 27 0.48 K/A 
5 57 M Egyptian Hepatic -ve 94 76 1.11 L/S/K/A 
6 66 M Indian Renal -ve 379 15 0.90 L/S 
7 37 M Indian Renal -ve 74 110 0.10 Normal 
8 74 M Indian Renal -ve 181 33 0.10 S/K 
9 63 M Indian Renal -ve 156 40 2.52 S/K/A 
10 62 M Indian Renal -ve 239 25 2.98 S/K 
11 68 F Indian - Punjabi Renal -ve 186 24 2.97 S/K/A 
12 75 F Indian Renal -ve 183 25 0.10 L/S/K/A 
13 69 M Pakistani Renal -ve 178 34 0.10 L/S/K 
14 66 M Pakistani Renal -ve 424 HD 0.12 A 
15 67 F Pakistani Renal -ve 284 15 1.06 S 
16 59 F Pakistani Renal -ve 131 38 0.20 S/K/A 
17 55 M Pakistani Renal -ve 127 53 0.51 S/K 
18 75 M Pakistani - Kashmiri Hepatic B & C 114 56 0.10 L/S/K/A 
19 70 M Pakistani - Punjabi Renal -ve 213 20 0.65 S/K 
20 71 F Punjabi Renal B 143 32 1.74 S/K 
21 53 M Sudanese Hepatic C 80 93 0.10 S 
22 54 F Sudanese Renal -ve 562 HD Anuric L/S/K 
23 56 F Mexican Rectal C 57 100 0.10 L/S 
24 73 F Indian Renal -ve 206 21 0.18 L/S/K 
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1 + - - - 0 30 0.17 N 
2 + + - - 0 24 0.10 N 
3 + + - + 0 44 0.47 N 
4 + - + - 0 27 0.48 N 
6 + + + + 0 15 0.90 Y 
7 + - - + 0 110 0.10 N 
8 + + - + 0 33 0.10 N 
9 - + + + 0 40 2.52 Y 
10 + - - + 1 25 2.98 N 
11 - + + + 1 24 2.97 Y 
12 - - - + 0 25 0.10 Y 
13 + + - + 0 34 0.10 N 
14 + + - + 1 HD 0.12 N 
15 + + - + 0 15 1.06 Y 
16 + + - + 0 38 0.20 Y 
17 + + - - 0 53 0.51 N 
19 + + - - 0 20 0.65 Y 
20 + + - - 0 32 1.74 Y 
22 + + - + 0 HD Anuric Y 




Table 3.  Comparison of rate of GFR loss in ALECT2 amyloidosis and hereditary renal amyloidosis 
 
Type of Amyloid Number Mean eGFR loss per year 
ml/min/year 
Leucocyte chemotactic factor 2 amyloidosis (ALECT2) 22 4.2 
Lysozyme (ALys) 7 4.7 
Apolipoprotein A-1 (AApoAI) 24 6.2 






Figure 1.  Histology in ALECT2 amyloidosis:  A)  Congo red staining of a renal biopsy 
specimen showing amyloid in all renal compartments including the glomeruli, renal 
tubules, vessels and interstitium.  B)  Apple green birefringence when viewed under 
cross polarized light. C)  Immunohistochemical staining with an antibody against 
LECT2 showing specific staining of the amyloid which is completely abrogated by 
prior absorption of the antibody with purified LECT2.  D)  Congo red staining of a liver 
biopsy specimen viewed under Brightfield light showing amyloid in vessels and portal 
tract. E)  Characteristic immunofluorescence of amyloid after Congo red staining and 
F) Immunohistochemical staining with an antibody against LECT2 showing specific 
staining of the amyloid. 
 
Figure 2.  Serial SAP scintigraphy in ALECT2 amyloidosis.  SAP anterior whole body 
SAP scans, taken 10 years apart, in a patient with ALECT2 amyloidosis showing 
absence of amyloid accumulation in the liver or spleen over this time period.   
 
Figure 3.  Outcome in ALECT2 amyloidosis.  A)  Patient survival in ALECT2 
amyloidosis by Kaplan Meier analysis.  Median estimated survival was 15.2 years.  
B)  Renal survival, defined as time from diagnosis to renal replacement therapy, in 
ALECT2 amyloidosis in comparison to other untreated renal amyloidoses including 
AApoAI, ALys, and AFib amyloidosis. 
